Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 22
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
AN2 Therapeutics Inc
ANTX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$3.64
0.04
1.11%
Últ. Act.: Oct 22, 4:00 PM
$3.64
0.04
1.11%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
AN2 Therapeutics Financials
AN2 Therapeutics (ANTX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
AN2 Therapeutics Q2 EPS $(0.18) Beats $(0.27) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.27) by 33.33 percent. This is a 14.29 percent increase over losses of $(0.21) per share from
Benzinga Newsdesk
PRO
AN2 Therapeutics Q1 EPS $(0.29) Misses $(0.23) Estimate
Benzinga Newsdesk
PRO
AN2 Therapeutics Q4 EPS $(0.29) Misses $(0.24) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.24) by 20.83 percent. This is a 16 percent decrease over losses of $(0.25) per share from
Benzinga Newsdesk
PRO
AN2 Therapeutics Q3 EPS $(0.31) Misses $(0.30) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.30) by 4.73 percent. This is a 27.91 percent increase over losses of $(0.43) per share from
Benzinga Newsdesk
PRO
AN2 Therapeutics Q2 EPS $(0.21) Beats $(0.30) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.30) by 30.69 percent. This is a 56.25 percent increase over losses of $(0.48) per share from
Benzinga Newsdesk
PRO
AN2 Therapeutics Q1 GAAP EPS $(0.35) Misses $(0.26) Estimate
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.26) by 34.62 percent. This is a 37.5 percent increase over losses of $(0.56) per share from
Benzinga Newsdesk
